Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with known oncogenic drivers including Merkel cell polyomavirus (MCPyV) and UV-induced DNA damage.
• The tumor microenvironment in MCC is characterized by MCPyV-specific T cells and immunosuppression, indicating its immunogenic nature.
• Immunotherapy, specifically anti-PD-1/PD-L1 blockade, has significantly improved outcomes for advanced MCC, achieving response rates of 50-70% in first-line treatment.

Purpose of the Study:

• To review current management guidelines for advanced Merkel cell carcinoma.
• To explore future therapeutic perspectives, focusing on molecular pathways, targeted therapies, and immune-based strategies.
• To address challenges of acquired resistance and contraindications to immune checkpoint inhibitors.

Main Methods:

• Literature review of current management guidelines for MCC.
• Analysis of molecular pathways implicated in MCC oncogenesis and progression.
• Evaluation of emerging targeted therapies and novel immune-based strategies.

Main Results:

• Anti-PD-1/PD-L1 blockade offers substantial benefits in first-line treatment for advanced MCC.
• A significant subset of patients develop acquired resistance or have contraindications to current immunotherapies.
• Understanding MCC's immunogenic properties and molecular landscape is crucial for developing next-generation treatments.

Conclusions:

• Novel therapeutic strategies are essential to overcome resistance and expand treatment options for advanced MCC.
• Combination therapies involving targeted agents or novel immune strategies with anti-PD-1/PD-L1 inhibitors hold promise.
• Future treatments aim to enhance anti-tumor immune responses and improve outcomes for patients with advanced MCC.